We propose that compounds that modulate the deubiquitinase activity of either USP33 or STAMBP may be of therapeutic use in the treatment of neuroendocrine tumors that result from impaired GCGR trafficking and signaling. The gene discussed is USP33; the disease is neuroendocrine neoplasm.